Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000261818

Medchemexpress LLC L-aspartic acid β-hydroxamate, serine racemase inhibitor | 1955-68-6 | MFCD00050389 | 98.0% | C4H8N2O4 | 10MG
SDP

Catalog No. 5000261818
Encompass_Preferred

L-Aspartic acid β-hydroxamate is an amino acid derivative in which the β-carboxyl of L-aspartic acid is converted to a hydroxamate. Supplied as a solid for research use, it is used as a metal-binding motif and enzyme inhibitor scaffold in biochemical and medicinal chemistry studies.

  • High purity (98.0%) for reliable experimental results.
  • Powder form suitable for storage and formulation.
  • Stable when stored at -20°C in powder form.
  • Useful as a hydroxamate-containing building block and enzyme inhibitor motif.
  • Available in small research quantities for screening and synthesis.

Catalog No. 50-002-61818 Supplier Medchemexpress LLC Supplier No. HY13445010MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

L-Aspartic acid β-hydroxamate is an amino acid derivative in which the β-carboxyl of L-aspartic acid is converted to a hydroxamate. Supplied as a solid for research use, it is used as a metal-binding motif and enzyme inhibitor scaffold in biochemical and medicinal chemistry studies.

  • High purity (98.0%) for reliable experimental results.
  • Powder form suitable for storage and formulation.
  • Stable when stored at -20°C in powder form.
  • Useful as a hydroxamate-containing building block and enzyme inhibitor motif.
  • Available in small research quantities for screening and synthesis.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.